Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding

Xinyi LI; Jiaojiao LI; Wei SUN

doi:10.12449/JCH240816

Volume 40 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(8): 1605-1611

PDF( 1030 KB)

Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding

DOI: 10.12449/JCH240816

Department of Infectious Diseases，The First Affiliated Hospital of Soochow University，Suzhou，Jiangsu 215000，China

Research funding:

National Major Science and Technology Special Project of the 13th Five-Year Plan Period (2017ZX10203201002-002);

Suzhou Health Youth Backbone Talent “National Tutorial System” Training Project (20190013990009);

Tianqing Liver Disease Research Foundation (TQGB20210134)

More Information

Corresponding author: SUN Wei， 20563470@qq.com （ORCID： 0000-0002-8278-3488）
Received Date: 2023-11-07
Accepted Date: 2023-11-29
Published Date: 2024-08-25

Abstract

Abstract

Objective To establish a nomogram prediction model for the development of overt hepatic encephalopathy （OHE） in patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic shunt （TIPS） after esophagogastric variceal bleeding， and to evaluate the predictive ability of the model. Methods This study was conducted among 113 patients with esophagogastric variceal bleeding due to liver cirrhosis who were admitted to The First Affiliated Hospital of Soochow University from January 2020 to December 2022 and underwent TIPS after failed medical or endoscopic therapy. All patients were followed up for 6 months after surgery， and according to the presence or absence of OHE after TIPS， they were divided into OHE group with 32 patients and non-OHE group with 81 patients. Related data were collected from all patients， including clinical data， routine blood test results， serum biochemistry， and coagulation test results. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. The multivariate Logistic regression analysis was used to investigate the independent risk factors for the onset of OHE after TIPS， and then a nomogram prediction model was established. The index of concordance （C-index） was calculated and the calibration curve was plotted to evaluate the predictive ability of the model， and the clinical decision curve was plotted to analyze the net clinical benefit of the model. The receiver operating characteristic （ROC） curve was used to validate the predictive ability of the model. Results There were significant differences between the OHE group and the non-OHE group in age， diabetes， Child-Pugh class， ascites， main portal vein diameter before surgery， gamma-glutamyl transpeptidase （GGT） level， prothrombin time， and Freiburg index of post-TIPS survival （FIPS） score （all P<0.05）. The multivariate Logistic regression analysis showed that Child-Pugh class （odds ratio ［OR］=17.498， 95% confidence interval ［CI］： 2.561‍ ‍—‍ ‍119.548， P=0.004）， main portal vein diameter before surgery （OR=1.361， 95%CI： 1.057‍ ‍—‍ ‍1.752， P=0.017）， GGT （OR=1.032， 95%CI： 1.013‍ ‍—‍ ‍1.052， P=0.001）， and FIPS score （OR=2.838， 95%CI： 1.277‍ ‍—‍ ‍6.311， P=0.010） were independent influencing factors for the development of OHE after TIPS. The nomogram model established based on the above four indicators had a C-index of 0.875， good fitting of the calibration curve， and an area under the ROC curve of 0.875 （95%CI： 0.799 ‍—‍ 0.929， P<0.001）， and the decision curve analysis showed that the 0.3 ‍—‍ 0.9 threshold probability model had a good net benefit. Conclusion Child-Pugh class， main portal vein diameter before surgery， GGT， and FIPS score have a certain value in predicting the development of OHE after TIPS in patients with esophagogastric variceal bleeding due to liver cirrhosis， and the nomogram model established based on these indicators can be used to individually predict the onset of OHE after TIPS in patients with esophagogastric variceal bleeding due to liver cirrhosis.
- Liver Cirrhosis,
- Esophageal and Gastric Varices,
- Portasystemic Shunt， Transjugular Intrahepatic,
- Hepatic Encephalopathy,
- Nomograms

FullText(HTML)

References(23)

References

[1]	LESMANA CRA, RAHARJO M, GANI RA. Managing liver cirrhotic complications: Overview of esophageal and gastric varices[J]. Clin Mol Hepatol, 2020, 26( 4): 444- 460. DOI: 10.3350/cmh.2020.0022.
[2]	LYU Y, FAN DM, HAN GH. Application status and future prospect of transjugular intrahepatic portosystemic shunt in gastroesophageal variceal bleeding in liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 6): 1229- 1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004. 吕勇, 樊代明, 韩国宏. 经颈静脉肝内门体分流术在肝硬化食管胃底静脉曲张破裂出血中的应用现状与未来展望[J]. 临床肝胆病杂志, 2022, 38( 6): 1229- 1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004.
[3]	ZHANG K, LIU JL, LIU YL, et al. The 3D model was constructed by computer based on CT thin-slice scanning data to guide the clinical observation of the clinical effect of intrahepatic portal shunt through jugular vein in the treatment of portal hypertension complicated with gastrointestinal bleeding in cirrhosis[J]. Clin J Med Offic, 2023, 51( 6): 655- 656, 660. DOI: 10.16680/j.1671-3826.2023.06.28. 张凯, 刘晶磊, 刘燚隆, 等. 应用CT薄层扫描数据电脑构建3D模型指导经颈静脉肝内门体分流术治疗肝硬化门脉高压合并消化道出血临床效果观察[J]. 临床军医杂志, 2023, 51( 6): 655- 656, 660. DOI: 10.16680/j.1671-3826.2023.06.28.
[4]	STEPANOVA M, MISHRA A, VENKATESAN C, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009[J]. Clin Gastroenterol Hepatol, 2012, 10( 9): 1034- 1041. DOI: 10.1016/j.cgh.2012.05.016.
[5]	TONG H, GAN C, WEI B, et al. Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis[J]. J Dig Dis, 2021, 22( 1): 31- 40. DOI: 10.1111/1751-2980.12957.
[6]	BETTINGER D, STURM L, PFAFF L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival[J]. J Hepatol, 2021, 74( 6): 1362- 1372. DOI: 10.1016/j.jhep.2021.01.023.
[7]	CAI WM, ZHENG BS, LIN XR, et al. Prediction of patient hepatic encephalopathy risk with Freiburg index of post-TIPS survival score following transjugular intrahepatic portosystemic shunts: A retrospective study[J]. Int J Gen Med, 2022, 15: 4007- 4016. DOI: 10.2147/IJGM.S359918.
[8]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34( 10): 2076- 2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007. 中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34( 10): 2076- 2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.
[9]	BAJAJ JS, CORDOBA J, MULLEN KD, et al. Review article: The design of clinical trials in hepatic encephalopathy: An International Society for Hepatic Encephalopathy and Nitrogen Metabolism(ISHEN) consensus statement[J]. Aliment Pharmacol Ther, 2011, 33( 7): 739- 747. DOI: 10.1111/j.1365-2036.2011.04590.x.
[10]	MA JL, CHEN X, HE LL, et al. Value of Child-Pugh score, Model for End-Stage Liver Disease score, MELD combined with serum sodium concentration, APASAL score, and R-score in predicting rebleeding and death in cirrhotic patients with esophagogastric variceal bleeding[J]. J Clin Hepatol, 2020, 36( 6): 1278- 1283. DOI: 10.3969/j.issn.1001-5256.2020.06.018. 马佳丽, 陈旭, 何玲玲, 等. Child-Pugh评分、MELD评分、MELD-Na评分、APASAL评分和R评分对肝硬化伴食管胃静脉曲张再出血及死亡的预测价值[J]. 临床肝胆病杂志, 2020, 36( 6): 1278- 1283. DOI: 10.3969/j.issn.1001-5256.2020.06.018.
[11]	Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Digestive Endoscopology of Chinese Medical Association. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2023, 39( 3): 527- 538. DOI: 10.3760/cmaj.cn501113-20220824-00436. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2023, 39( 3): 527- 538. DOI: 10.3760/cmaj.cn501113-20220824-00436.
[12]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension(2019 edition)[J]. J Clin Hepatol, 2019, 35( 12): 2694- 2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010. 中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2694- 2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
[13]	GAO Y. Predictive value of Freiburg survival index(FIPS) for survival of patients with cirrhosis and portal hypertension treated by transjugular intrahepatic portosystemic shunt[D]. Changchun: Jilin University, 2022. 高扬. 弗莱堡术后生存指数(FIPS)对经颈静脉肝内门体分流术治疗的肝硬化门脉高压患者生存期的预测价值[D]. 长春: 吉林大学, 2022.
[14]	LIU Y, ZHOU ZZ, LIU G, et al. The characteristics and risk factors of hepatic encephalopathy after emergent TIPS operation in patients with bleeding from esophageal and gastric varices[J]. Chin Hepatol, 2022, 27( 6): 658- 661. DOI: 10.3969/j.issn.1008-1704.2022.06.014. 刘益, 周自忠, 刘刚, 等. 食管胃底静脉曲张破裂出血患者急诊TIPS术后肝性脑病发生特征及危险因素分析[J]. 肝脏, 2022, 27( 6): 658- 661. DOI: 10.3969/j.issn.1008-1704.2022.06.014.
[15]	ICHAI P, SAMUEL D. Etiology and prognosis of fulminant hepatitis in adults[J]. Liver Transpl, 2008, 14( Suppl 2): S67- S79. DOI: 10.1002/lt.21612.
[16]	KRISHNARAO A, GORDON FD. Prognosis of hepatic encephalopathy[J]. Clin Liver Dis, 2020, 24( 2): 219- 229. DOI: 10.1016/j.cld.2020.01.004.
[17]	FONIO P, DISCALZI A, CALANDRI M, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt(TIPS) according to its severity and temporal grading classification[J]. Radiol Med, 2017, 122( 9): 713- 721. DOI: 10.1007/s11547-017-0770-6.
[18]	YIN XC, ZHANG F, GUO HW, et al. A nomogram to predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients[J]. Sci Rep, 2020, 10( 1): 9381. DOI: 10.1038/s41598-020-65227-2.
[19]	LIU J, ZHOU C, WANG Y, et al. The combination of Child-Pugh score and quantitative CT-based spleen volume could predict the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. Abdom Radiol(NY), 2021, 46( 7): 3464- 3470. DOI: 10.1007/s00261-021-02972-6.
[20]	WEISS N, BARBIER SAINT HILAIRE P, COLSCH B, et al. Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy[J]. J Hepatol, 2016, 65( 6): 1120- 1130. DOI: 10.1016/j.jhep.2016.07.046.
[21]	MCMILLIN M, FRAMPTON G, QUINN M, et al. Bile acid signaling is involved in the neurological decline in a murine model of acute liver failure[J]. Am J Pathol, 2016, 186( 2): 312- 323. DOI: 10.1016/j.ajpath.2015.10.005.
[22]	AMPUERO J, RANCHAL I, DEL MAR DÍAZ-HERRERO M, et al. Role of diabetes mellitus on hepatic encephalopathy[J]. Metab Brain Dis, 2013, 28( 2): 277- 279. DOI: 10.1007/s11011-012-9354-2.
[23]	YIN XC, ZHANG F, XIAO JQ, et al. Diabetes mellitus increases the risk of hepatic encephalopathy after a transjugular intrahepatic portosystemic shunt in cirrhotic patients[J]. Eur J Gastroenterol Hepatol, 2019, 31( 10): 1264- 1269. DOI: 10.1097/MEG.0000000000001452.

Relative Articles

[1]	Linna YUAN, Yihui CHEN, Hengbin NA, Jie LU, Ye LIU, Wu LI. Primary biliary cholangitis with metabolic associated fatty liver disease： Clinical features and risk factors[J]. Journal of Clinical Hepatology, 2024, 40(8): 1598-1604. doi: 10.12449/JCH240815
[2]	Nan GENG, Wenjing NI, Fajuan RUI, Jie LI. Chronic hepatitis B virus infection and metabolic associated fatty liver disease： The known and unknown aspects[J]. Journal of Clinical Hepatology, 2024, 40(3): 441-445. doi: 10.12449/JCH240301
[3]	Yingdie ZHU, Zhijiao ZHANG, Guilin ZHANG, Yunkun GAO, Mengyao ZHENG, Hua HUANG, Gongfang ZHAO. Association of metabolic associated fatty liver disease with carotid atherosclerotic plaque and stenosis[J]. Journal of Clinical Hepatology, 2024, 40(8): 1591-1597. doi: 10.12449/JCH240814
[4]	Tao JIANG, Wenxian OUYANG, Yanfang TAN, Zhen KANG, Shuangjie LI. Changes in the frequency, phenotype, and function of mucosal-associated invariant T lymphocytes in peripheral blood of children with metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(3): 562-566. doi: 10.3969/j.issn.1001-5256.2023.03.012
[5]	Xiaodong ZHOU, Na TIAN, Minghua ZHENG. Excerpt of an international multidisciplinary consensus statement on MAFLD and the risk of CVD （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2336-2339. doi: 10.3969/j.issn.1001-5256.2023.10.010
[6]	Shuang ZHANG, Xiaohui LIU, Gang WANG, Li ZHANG, Yunjie ZHU, Jian WU, Yali LIU, Jing ZHANG. Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population[J]. Journal of Clinical Hepatology, 2022, 38(3): 547-552. doi: 10.3969/j.issn.1001-5256.2022.03.011
[7]	Ling LUO, Xianhua LIAO, Bihui ZHONG. Research advances in vitamin D deficiency and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1641-1645. doi: 10.3969/j.issn.1001-5256.2022.07.034
[8]	Yunxia WU, Chengliang LI, Xiaolei LI, Zhaoxiao LUO, Tianshun REN. Correlation between cardiometabolic index and metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(10): 2247-2251. doi: 10.3969/j.issn.1001-5256.2022.10.010
[9]	Enrui XIA, Gege TIAN, Suyan ZHANG, Shunzhen ZHANG. Effect of Quzhi Ruangan prescription on the farnesoid X receptor-fibroblast growth factor 19 pathway in rats with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1069-1074. doi: 10.3969/j.issn.1001-5256.2022.05.018
[10]	Zhenyang SHEN, Xiaobo CAI, Lungen LU. Application of farnesoid X receptor agonists in treatment of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1402-1405. doi: 10.3969/j.issn.1001-5256.2022.06.038
[11]	Zhenzhen ZHANG, Yaoyi ZHANG, Kai WANG, Chenguang TIAN. Effect of dapagliflozin on metabolic markers and autonomic function in patients with type 2 diabetes mellitus and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(12): 2849-2853. doi: 10.3969/j.issn.1001-5256.2021.12.023
[12]	Lidan YANG, He HE, Zhenmei AN. Role of intestinal flora in metabolic-associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2231-2235. doi: 10.3969/j.issn.1001-5256.2021.09.046
[13]	Qianqian XIAO, Mengyu WANG, Jiangao FAN. Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease (Treatment Part)[J]. Journal of Clinical Hepatology, 2021, 37(1): 41-45. doi: 10.3969/j.issn.1001-5256.2021.01.009
[14]	Junzhao YE, Yansong LIN, Bihui ZHONG. Research advances in dietary intervention in the treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(3): 709-713. doi: 10.3969/j.issn.1001-5256.2021.03.042
[15]	Lei MIAO, Liangjie TANG, Jiangao FAN, Minghua ZHENG. Acute-on-chronic liver failure in patients with metabolic associated fatty liver disease: Past, Present, and Future[J]. Journal of Clinical Hepatology, 2021, 37(4): 761-764. doi: 10.3969/j.issn.1001-5256.2021.04.004
[16]	Sutong LIU, Kaiqi SU, Chenlu ZHAO, Lihui ZHANG, Wenxia ZHAO. Research advances in medical treatment of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 947-950. doi: 10.3969/j.issn.1001-5256.2021.04.048
[17]	Jiahui LYU, Xiaofei LI, Lianyi GUO. Association between metabolic associated fatty liver disease and sleep disorders[J]. Journal of Clinical Hepatology, 2021, 37(12): 2854-2860. doi: 10.3969/j.issn.1001-5256.2021.12.024
[18]	Xue Rui, Fan JianGao. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1224-1227. doi: 10.3969/j.issn.1001-5256.2020.06.007
[19]	LIU YingYing, LIU YuPing, LIU YouRen, SUN Ping. Implementation of aerobic exercise intervention in patients with metabolic associated fatty liver disease:A prospective study[J]. Journal of Clinical Hepatology, 2020, 36(11): 2467-2472. doi: 10.3969/j.issn.1001-5256.2020.11.014
[20]	Zhang KaiLing, Li LiangPing. Mechanism of action of intestinal farnesoid X receptor in nonalcoholic fatty liver disease and related targeted drugs[J]. Journal of Clinical Hepatology, 2020, 36(5): 1160-1163. doi: 10.3969/j.issn.1001-5256.2020.05.047

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (318) PDF downloads(28)

Establishment and evaluation of a nomogram prediction model for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis and esophagogastric variceal bleeding

DOI: 10.12449/JCH240816

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content